Syneron Announces US and Canada Launch of CO2RE System Following FDA and Health Canada Clearance for the System

New fractional CO2 resurfacing laser offers practitioners broader and highly effective treatment options

Nov 30, 2010, 00:01 ET from Syneron Medical Ltd.

YOKNEAM, Israel and IRVINE, Calif., Nov. 30, 2010 /PRNewswire/ -- Syneron Medical Ltd. (Nasdaq: ELOS),, the global leader in the medical aesthetic device marketplace, announced today the US Food and Drug Administration (FDA) and Health Canada clearance and commercial launch of its highly flexible CO2RE CO2 resurfacing system. CO2RE is a versatile fractional CO2 system that offers the unique ability to treat both superficial and deep skin layers simultaneously with precision-control over the intensity, pattern and depth of ablation. This patent-pending technology is the first to receive FDA clearance for all of its operating modes, including the four major fractional treatment modes. The system can be used for fractional CO2 resurfacing and traditional ablation, and is ideal for skin rejuvenation, wrinkle reduction, scar reduction and other aesthetic procedures.

“We received very positive physician feedback during the international roll-out of the CO2RE system and we are excited to begin offering it in the United States and Canada, giving our customers more choices and greater flexibility to meet their individual practice needs. With the addition of CO2RE, we now offer a complete range of product solutions that address physicians’ and patients' needs across a wide range of facial rejuvenation treatment categories,” said Louis P. Scafuri, Chief Executive Officer of Syneron. Mr. Scafuri added, “The launch of CO2RE shows the strength of our globalized approach to research and development. The product was developed by Inlight Inc., San-Diego, Calif. which was acquired by Syneron at the end of 2008. Inlight brought to Syneron the most advanced scanner and ablative laser technology which, in combination with Syneron’s know-how in light tissue interaction, enabled us to bring to the market the most advanced and versatile system for a wide range of ablative skin rejuvenation procedures.”

"We've been very happy with the results that we've seen using CO2RE.  It has a lot of versatility and we find it works well for both fractionated ablative resurfacing as well as traditional ablative resurfacing," said Brian Zelickson, MD, a board certified dermatologist at the Zel Skin and Laser Specialists.  

E. Victor Ross, MD, at the Scripps Clinic Carmel Valley Laser and Cosmetic Dermatology commented, "One of CO2RE's advantages is the handpiece, which is very easy to hold. In comparison to other fractional handpieces the CO2RE handpiece is thin, lightweight and easy to maneuver around the skin during treatments."

About CO2RE

The new CO2RE fractional CO2 resurfacing system is a lighter, faster and more versatile solution for skin resurfacing, wrinkle and scar reduction, and other traditional CO2 applications. CO2RE is the only CO2 laser to offer multi-depth pulse technology, delivering precisely fractionated beam patterns to treat multiple layers of the epidermis and dermis simultaneously.

About Syneron Medical Ltd.

Syneron Medical Ltd. – a company devoted to real technology, real science and real results – is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. With its innovative approach to aesthetic treatments, Syneron has now entered into one of the largest in-demand applications, skin lightening. Founded in 2000, the corporate, R&D and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

Additional information can be found at


Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements.  There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time.  If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document.  Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change.  However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so.  The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.


Asaf Alperovitz, Chief Financial Officer

+ 972 73 244 2283


Nick Laudico/Zack Kubow, The Ruth Group


Email: /

SOURCE Syneron Medical Ltd.